Resistance to chemotherapy: new treatments and novel insights into an old problem
Open Access
- 29 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (3), 387-391
- https://doi.org/10.1038/sj.bjc.6604510
Abstract
Resistance to cancer chemotherapeutic treatment is a common phenomenon, especially in progressive disease. The generation of cellular models of drug resistance has been pivotal in unravelling the main effectors of resistance to traditional chemotherapy at the molecular level (i.e. intracellular drug inactivation, detoxifying systems, defects in DNA repair, apoptosis evasion, membrane transporters and cell adhesion). The development of targeted therapies has also been followed by resistance, reminiscent of an evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous leukaemia. Although traditionally associated with the last stages of the disease, recent findings with minimally transformed pretumorigenic primary human cells indicate that the ability to generate drug resistance arises early during the tumorigenic process, before the full transformation. Novel technologies, such as genome profiling, have in certain cases predicted the outcome of chemotherapy and undoubtedly have tremendous potential for the future. In addition, the novel cancer stem cell paradigm raises the prospect of cell-targeted therapies instead of treatment directed against the whole tumour.Keywords
This publication has 46 references indexed in Scilit:
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Nature Reviews Cancer, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Pharmacokinetics in cancer chemotherapyEuropean Journal of Cancer, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerThe New England Journal of Medicine, 2004
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002